Cite
HARVARD Citation
Trauner, M. et al. (2019). The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 70 (3), pp. 788-801. [Online].